Nampak Ltd (PK) News - NPKLD

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty...

Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results

PETALUMA, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quarterly Net Loss Reduced by 53% Compared to Prior...

Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division

PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty...

Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock

PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today...

Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock

PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today...

Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock

PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today...

Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results

Quarterly and YTD Reduction in Net Loss Compared to Prior Year PETALUMA, Calif., Nov. 14, 2019 (GLOBE...

Sonoma Pharmaceuticals Announces Management Changes

Agreement with CEO and Interim CFO Bubba Sandford endsAmy Trombly Appointed as Interim CEO John Dal Poggetto...

Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results

Strong Quarter-Over-Quarter Performance 26% Increase in U.S. Product Revenue46% Increase in Dermatology...

Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule

PETALUMA, Calif., July 12, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty...

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results

Strong Annual Year-Over-Year Growth with 14% Revenue Growth Strong Quarter-Over-Quarter Growth with 20...

Sonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock

PETALUMA, Calif., June 19, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals...

Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million

PETALUMA, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma Pharmaceuticals...

Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures

PETALUMA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Specialty pharmaceutical company Sonoma...

Sonoma Pharmaceuticals Announces Management Changes

CEO Jim Schutz and CFO Robert Miller Step DownFrederick (Bubba) Sandford Appointed as New CEO and Interim CFO...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nampak Ltd (PK) (NPKLD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

NPKLD News

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results

Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division

Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock

Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock

Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results

Sonoma Pharmaceuticals Announces Management Changes

Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results

Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results

Sonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock

Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million

Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures

Sonoma Pharmaceuticals Announces Management Changes

NPKLD Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Nampak Ltd (PK) (NPKLD) News

Nampak Ltd (PK) (NPKLD)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

NPKLD News

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results

Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division

Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock

Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock

Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results

Sonoma Pharmaceuticals Announces Management Changes

Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results

Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results

Sonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock

Sonoma Pharmaceuticals Sells Animal Health Rights in Asia and Europe for $2.7 million

Sonoma Pharmaceuticals Announces Substantial Cost-Cutting Measures

Sonoma Pharmaceuticals Announces Management Changes

NPKLD Discussion

Your Recent History